Martin Little

6PUBLICATIONS
52CO-AUTHORS
Innate immunityHaematological tumoursGene expression (incl. microarray and other genome-wide approaches)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 07, 2026
Anti-CMV IgG titer determines organ-specific protection toward immune checkpoint blockade-induced toxicities.

|Nov 06, 2025
The immunomodulatory role of human cytomegalovirus in cancer in the era of checkpoint immunotherapy.

Julia Bremke, Cecilia Jay, Martin Little

|Jul 25, 2025
Defining the genetic determinants of CD8+ T cell receptor repertoire in the context of immune checkpoint blockade.

Esther S Ng, Gusztav Milotay, Orion Tong

|Apr 24, 2025
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.

Gusztav Milotay, Martin Little, Robert A Watson

|Sep 01, 2022
Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic.

Aglaia Skolariki, Jamie D'Costa, Martin Little

|Aug 19, 2022
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer.

Susana Banerjee, Vasiliki Michalarea, Joo Ern Ang

Pageof 1

Frequent Collaborators

4 joint publications

Benjamin P Fairfax

3 joint publications

Orion Tong

2 joint publications

James J Gilchrist

2 joint publications

Chelsea A Taylor